Stability of astigmatism, keratometric parameters and improvement in BCVA in our study indicates the efficacy of CXL to prevent progression in PMD. Group 1 Codes: ICD-10 Codes that Support Medical Necessity Group 1 Paragraph: N/A Group 1 Codes: Group 1 Medical Necessity ICD-10 Codes Asterisk Explanation: All the codes within the asterisked range from the first code to the last code apply. Collagen cross linking is a safe and effective method to prevent progression in PMD. None of the treated eyes developed side effect of notable severity. Keratometric astigmatism decreased by 1.13 D (P = 0.2) measured by Scheimpflug imaging and by 1.4 D (P = 0.13) as measured by topography. There was no significant difference in the pre and post-op spherical equivalent (P = 0.38) and the mean cylinder decreased by 0.53 ± 0.81 D (P = 0.19) which was not significant. logMAR UCVA (uncorrected visual acuity) and BCVA (best corrected visual acuity) with spectacles at 6 months and at final follow-up showed improvement in all groups, which were significant in group C. Visual acuity, retinoscopic refraction, corneal topography, tomography and pachymetry were examined before and every six months after surgery for the first two years and then annually. The eyes were divided as per riboflavin used namely hypo-osmolar, HPMC (hydroxy propyl methyl cellulose), iso-osmolar into group A, B and C respectively. ![]() ![]() A retrospective interventional study involving 15 eyes of 10 patients with pellucid marginal degeneration (PMD) were treated with collagen cross linking (CXL) to evaluate itslong term effects on such patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |